Integrate the voices of different stakeholders to enhance and transform your market access strategy.
At this summit you can source insights from government, private payers, patients and pharmacists to stay up-to-date on the most recent developments in the field and find opportunities for collaboration on new initiatives, projects and partnerships.
Government budgets are shrinking, while the cost of producing innovative drugs is increasing. Collaboration and cooperation are essential to the well-being of the industry and the general population. Learn how you can engage your stakeholders to streamline bureaucratic processes and cut costs. Prepare your market access strategy to be adaptable to upcoming changes and ensure continued relevance.
Make sure your organization is on the cutting edge of market access practice to effectively deliver benefits for both your bottom line and the health care system!
Ashley Metz has been the Director of Pharmaceutical Policy and Appropriateness with the Government of Saskatchewan since November 2014.
Ashley previously spent five years in Saskatchewan’s Executive Council where she supported the creation of Canada’s Premiers’ Health Care Innovation Working Group (HCIWG). While Saskatchewan was the co-chair of the HCIWG, Ashley was involved in the establishment of the pan-Canadian Pharmaceutical Alliance as well as the Generic Pricing Framework.
During her time in the Saskatchewan Public Service Ashley has held positions in Labour Market Development as well as other roles within the Ministry of Health.
Ashley holds a Masters of Political Science from the University of Saskatchewan.
A career public servant, Doug has a background in international trade law, intellectual property policy, pharmaceutical industry issues and competition law enforcement.
Doug attended McGill University, the University of New Brunswick and l'Université de Moncton. He graduated law school in 1997 and was called to the Ontario Bar in 1999 after a clerkship with the Honourable Marc Noël of the Federal Court of Appeal.
In 2000, Doug was hired by Industry Canada to assist in the case management of two WTO-based legal challenges to Canada’s pharmaceutical patent regime brought by the US and EU. In 2006, Doug became the Director of the Patent and Trademark Policy Directorate at Industry Canada, where he led a number of legislative and regulatory initiatives under the Patent Act and Trademarks Act, including the development of Canada’s Access to Medicines Regime (CAMR) and pharmaceutical patent litigation reform. In 2009, Doug joined the Competition Bureau as Assistant Deputy Commissioner, Civil Matters Branch, where he was responsible for a number of high profile prosecutions under the Competition Act.
Doug became Executive Director of the PMPRB on October 28, 2013.
A results-driven healthcare leader with three decades of innovative achievement in building and transforming organizations. A senior executive with experience in public and private sector, multinational and start-up healthcare organizations, Jane possesses an exceptional ability to vision the healthcare system from multiple vantage points. Jane has been at the forefront of policy transformation, generating and delivering compelling solutions to complex challenges. A passionate champion for patient-centred pharmacy practice advancement and value-driven outcomes, she is a sought-after speaker, collaborator and advisor.
Peter Gove, innovation leader, health management with Green Shield Canada (GSC), has oversight for initiatives under GSC’s Change4Life™ banner. Change4Life™ is aimed at supporting Canadians to better manage their health. The initiative utilizes advanced analytics to proactively identify plan participants who are at risk of developing, or who have developed a chronic disease and to reach out to them with focused programs.
Prior to coming to GSC, Peter was responsible for the national disability management and life insurance claims program for a large Canadian life insurance company.
Mr. Gove has a master’s degree in social work and is a registered social worker. Continuing his education, he started a PhD program in Applied Health Science at the University of Waterloo. He has presented internationally in the areas of health management and disability management and was the recipient of the 2014 Vision and Values Award presented by the Canadian Life and Health Insurance Association.
Beth Molloy-Whaley is the Senior Director of Consulting for Innomar Strategies, based out of our Head Office in Oakville, Ontario. She joined the company in May 2014. Beth has 25 years of pharmaceutical industry experience. Starting her Pharma career in sales, Beth has held senior level positions in Marketing, Sales Leadership, Market Access and Commercial Excellence for companies such as Bayer, GSK, Biogen Idec, and Hoffman-LaRoche. She has worked in multiple therapeutic areas in primary care, oncology and biologics. In addition to extensive pharmaceutical industry experience, Beth owned and operated an independent consulting firm assisting companies in Canada and internationally to develop strategic plans, improve processes and develop commercial talent.
Beth oversees the consulting services offered by Innomar in the areas of business strategy, market access, health outcomes evidence generation and optimization of the patient experience.
Before joining CADTH (Canadian Agency for Drugs and Technologies in Health) as the Director, Common Drug Review (CDR) and Rapid Response in March 2011, Dr. Chander Sehgal worked in the pharmaceutical industry for past six years in Canada across various functions including Medical Affairs, Reimbursement Planning and Health Economics and Outcomes Research. Chander completed a full-time MBA from the Richard Ivey School of Business, University of Western Ontario, London, Ontario in 2009 and specialized in healthcare stream. Chander has also completed a postgraduate program in Health Economics from the Center of Health Economics, University of York, York, UK. Chander’s current role is Director, CDR and Optimal Use of Drugs.